Eurofins-Cerep (ALECR) Stock Overview
Provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ALECR from our risk checks.
ALECR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Eurofins-Cerep SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €18,200.00 |
| 52 Week High | €21,200.00 |
| 52 Week Low | €15,800.00 |
| Beta | 0.47 |
| 1 Month Change | 0% |
| 3 Month Change | 3.41% |
| 1 Year Change | -16.51% |
| 3 Year Change | -18.02% |
| 5 Year Change | 145.95% |
| Change since IPO | 289.30% |
Recent News & Updates
Recent updates
The Market Doesn't Like What It Sees From Eurofins-Cerep SA's (EPA:ALECR) Revenues Yet
Jul 06
Investors Aren't Entirely Convinced By Eurofins-Cerep SA's (EPA:ALECR) Revenues
Oct 18Eurofins-Cerep SA's (EPA:ALECR) Subdued P/S Might Signal An Opportunity
Jun 26Eurofins-Cerep SA (EPA:ALECR) Screens Well But There Might Be A Catch
Sep 28Shareholder Returns
| ALECR | FR Life Sciences | FR Market | |
|---|---|---|---|
| 7D | 0% | 8.5% | 3.0% |
| 1Y | -16.5% | -1.8% | 5.4% |
Return vs Industry: ALECR underperformed the French Life Sciences industry which returned -4.5% over the past year.
Return vs Market: ALECR underperformed the French Market which returned 5.8% over the past year.
Price Volatility
| ALECR volatility | |
|---|---|
| ALECR Average Weekly Movement | 5.2% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FR Market | 10.6% |
| 10% least volatile stocks in FR Market | 2.1% |
Stable Share Price: ALECR has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ALECR's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 207 | Damien Vielliard | www.eurofins.fr/cerep/ |
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company’s research services include compound management, and high-throughput screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014.
Eurofins-Cerep SA Fundamentals Summary
| ALECR fundamental statistics | |
|---|---|
| Market cap | €91.80m |
| Earnings (TTM) | €7.15m |
| Revenue (TTM) | €40.49m |
Is ALECR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALECR income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.42k |
| Gross Margin | 43.18% |
| Net Profit Margin | 17.67% |
| Debt/Equity Ratio | 0.5% |
How did ALECR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 08:38 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eurofins-Cerep SA is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Guillaume Cuvillier | Gilbert Dupont |
| Cédric Moreau | Natixis S.A. |
| Rodolphe Besserve | Societe Generale Cross Asset Research |